Answers are grounded in this paper and cite their sources.
Reports efficacy of datopotamab deruxtecan versus docetaxel in advanced non-small cell lung cancer, highlighting new antibody-drug conjugate options.
Background: Despite advances in frontline therapy, most patients (pts) with adv/met NSCLC experience progression, and later-line chemotherapy with docetaxel-based regimens has limited benefit. Dato-DXd is an antibody-drug conjugate composed of a TROP2 directed monoclonal antibody covalently linked to a highly potent cytotoxic payload via a stable, tumor-selective, tetrapeptide-based cleavable linker. This is the first report of results from TROPION-Lung01 (NCT04656652), a randomized, global, open-label, phase 3 study comparing the efficacy and safety of Dato-DXd vs docetaxel in pts with adv/met NSCLC with or without actionable genomic alterations (AGAs).
No takes yet. Share an insight, caveat, or question.
Atmaca et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: